跳至主要内容
临床试验/NCT00468260
NCT00468260终止1 期

An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies-extension Study

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2007年5月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
12
试验地点
1
主要终点
Safety

研究概览

简要总结

To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Participation in study EPO906A2120E1
  • •Age ≥ 18 years of age
  • •Life expectancy ≥ 3 months
  • •Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist
  • •Completed all PK sampling in the core study

排除标准

  • •Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis
  • •Female patients who are pregnant or breast feeding
  • •Patients with a severe and/or uncontrolled medical disease
  • •Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Safety

Tolerability

Potential activity of patupilone once every 21 days in patients that completed the core study

次要结局

  • Objective response and tumor evaluation assessed by response evaluation criteria in solid tumors (RECIST)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验